CIC
ITOS

Cornercap Investment Counsel’s iTeos Therapeutics ITOS Stock Holding History

Cornercap Investment Counsel’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,119
Closed -$195K – 594
2024
Q2 		$195K Sell
13,119
-121
-0.9% -$1.73K 0.03% 543
2024
Q1 		$181K Hold
13,240
– – 0.03% 574
2023
Q4 		$145K Buy
13,240
+52
+0.4% +$515 0.02% 551
2023
Q3 		$144K Buy
13,188
+631
+5% +$8.07K 0.03% 517
2023
Q2 		$166K Hold
12,557
– – 0.03% 530
2023
Q1 		$171K Buy
+12,557
New +$225K 0.03% 514

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cornercap Investment Counsel's ITOS Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of iTeos Therapeutics (ITOS) in Q3 2024, closing a stake of 13,119 shares — an estimated $195K sold.

Cornercap Investment Counsel first reported a position in ITOS in Q1 2023 and held it in 6 quarters. The position peaked at $195K in Q2 2024. 150 funds tracked by Wall St. Rank hold ITOS as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining iTeos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 13,119 iTeos Therapeutics shares in Q3 2024, an estimated $195K.
  • Cornercap Investment Counsel first reported a position in iTeos Therapeutics in Q1 2023 and held it in 6 quarters.
  • Cornercap Investment Counsel's iTeos Therapeutics position peaked at $195K in Q2 2024.
  • 150 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.